Abstracts tagged "Anti-depressant"

Abstract Number: 2783 • 2017 ACR/ARHP Annual Meeting
Medications Associated with Osteoporotic Fracture Risk in Patients with Rheumatoid Arthritis
Gulsen Ozen¹, Sofia Pedro², Frederick Wolfe² and Kaleb Michaud¹, ¹Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²National Data Bank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Osteoporotic (OP) fractures are a major cause of disability, cost, and mortality in RA. Besides increased OP fracture risk, chronic inflammation and pain predispose…
Abstract Number: 2186 • 2016 ACR/ARHP Annual Meeting
Analgesic Use and Subsequent Risk of Falls in Participants with or at Risk of Knee Osteoarthritis
Wei-Hsuan Lo-Ciganic¹, Lysbeth Floden², Erin L. Ashbeck³, Lili Zhou¹ and C. Kent Kwoh^3,4, ¹Department of Pharmacy, Practice and Science, University of Arizona, College of Pharmacy, Tucson, AZ, ²Department Pharmacy, Practice and Science, University of Arizona, College of Pharmacy, Tucson, AZ, ³The University of Arizona Arthritis Center, Tucson, AZ, ⁴Rheumatology, University of Arizona, College of Medicine, Tucson, AZ
Background/Purpose: Analgesics including opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), antidepressants, and nutraceuticals are commonly used for pain relief in osteoarthritis (OA). Although it has been reported…
Abstract Number: 2118 • 2015 ACR/ARHP Annual Meeting
Prescription Medication Use in Community-Based US Adults with Chronic Low Back Pain: Nhanes 2009-2010
Anna Shmagel¹ and Robert Foley², ¹Rheumatic & Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN, ²Renal Diseases and Hypertension, University of Minnesota, Minneapolis, MN
Background/Purpose: Chronic low back pain (cLBP) is a significant public health problem. Establishing treatment guidelines has been difficult due to heterogeneity of research data. Little…
Abstract Number: L6 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety of Pregabalin in Patients with Fibromyalgia and Co-Morbid Depression Receiving Concurrent Antidepressant Therapy: A Randomized, 2-Way Crossover, Double-Blind, Placebo-Controlled Study
Lesley M. Arnold¹, Piercarlo Sarzi-Puttini², Pierre Arsenault³, Tahira Khan⁴, Pritha Bhadra Brown⁵, Andrew Clair⁵, Joseph Driscoll⁴, Jaren Landen⁴ and Lynne Pauer⁴, ¹Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, ²Azienda Ospedaliera Polo Universitario L. Sacco, Milano, Italy, ³Département de Médecine de Famille, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY
Background/Purpose: Fibromyalgia (FM) is characterized by chronic widespread pain and often associated with mood disorders including depression. Approximately 50–70% of FM patients have a lifetime…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].